Loss of interleukin-17 receptor D promotes chronic inflammation-associated tumorigenesis.
Center for Molecular Medicine, Maine Medical Center Research Institute
Receptors, Interleukin-17, Carcinogenesis, Cell Transformation, Neoplastic, Inflammation
Interleukin-17 receptor D (IL-17RD), also known as similar expression to Fgf genes (SEF), is proposed to act as a signaling hub that negatively regulates mitogenic signaling pathways, like the ERK1/2 MAP kinase pathway, and innate immune signaling. The expression of IL-17RD is downregulated in certain solid tumors, which has led to the hypothesis that it may exert tumor suppressor functions. However, the role of IL-17RD in tumor biology remains to be studied in vivo. Here, we show that genetic disruption of Il17rd leads to the increased formation of spontaneous tumors in multiple tissues of aging mice. Loss of IL-17RD also promotes tumor development in a model of colitis-associated colorectal cancer, associated with an exacerbated inflammatory response. Colon tumors from IL-17RD-deficient mice are characterized by a strong enrichment in inflammation-related gene signatures, elevated expression of pro-inflammatory tumorigenic cytokines, such as IL-17A and IL-6, and increased STAT3 tyrosine phosphorylation. We further show that RNAi depletion of IL-17RD enhances Toll-like receptor and IL-17A signaling in colon adenocarcinoma cells. No change in the proliferation of normal or tumor intestinal epithelial cells was observed upon genetic inactivation of IL-17RD. Our findings establish IL-17RD as a tumor suppressor in mice and suggest that the protein exerts its function mainly by limiting the extent and duration of inflammation.
Girondel, Charlotte; Lévesque, Kim; Langlois, Marie-Josée; Pasquin, Sarah; Saba-El-Leil, Marc K; Rivard, Nathalie; Friesel, Robert; Servant, Marc J; Gauchat, Jean-François; Lesage, Sylvie; and Meloche, Sylvain, "Loss of interleukin-17 receptor D promotes chronic inflammation-associated tumorigenesis." (2020). Maine Medical Center. 2011.